Telix at ANZSNM Annual Scientific Meeting 2025
Telix will have a strong presence at the 55th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2025), to be held in Melbourne, Australia from 23–25 May 2025.
Telix will feature prominently in the scientific program with eight oral and three poster presentations highlighting the Company’s late-stage and next-generation programs. Demonstrating its commitment to development and education in theranostics, Telix presentations include:
- Zolar study of TLX300-CDx (89Zr-olaratumab)[5], a theranostic approach in soft tissue sarcoma
- TLX250-CDx early access in Australia and Italy highlighting clinical utility in clear cell renal cell carcinoma (ccRCC)
- D2, a first-in-class, dual-chelator theranostic that could enable the use of imaging-therapy radiometal pairs of different elements[9]
- Artificial intelligence (AI) enabled PSMA-PET/CT[10] lesion delineation for prostate cancer
Breakfast Symposium and Nurses’ Workshop
Telix will also host a Breakfast Symposium showcasing real-world experience and impact on clinical decision making with TLX250-CDx, and clinical utility of PSMA-PET. Again we are pleased to support the Nurses’ Workshop in collaboration with with the Prostate Cancer Foundation of Australia (PCFA), NeuroEndocrine Cancer Australia (NECA) and the Peter MacCallum Cancer Centre in Melbourne.
Telix will be at booth #28, where visitors can learn more about Telix’s extensive late-stage theranostic pipeline in urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and hematology, our associated medical technologies and AI innovations, and opportunities for collaboration.
Telix Hosted Breakfast
Location: Meeting Room 203
Date and Time: Sunday, 25 May | 7:15 AM – 8:15 AM
Topics and Presenters:
- Enhancing cancer care with precision radiopharmaceuticals: Expanded access for renal cancers – Sze Ting Lee, Austin Health
- Early diagnosis with PSMA PET in prostate cancer – Michael Kitchener, Jones Radiology
Nurses Workshop
Location: Meeting Room 205
Date and Time: Saturday, 24 May | 12:30 PM – 1:30 PM
Topics and Presenters:
- Interpreting liver function tests – Emma Boehm, Peter MacCallum Cancer Centre
- Gallium-68 PET, FDG PET and other imaging modalities – Aaron Wong, Peter MacCallum Cancer Centre
- Managing toxicities in theranostics – Gabby Cehic AM, SA Health
- Radiation safety during radiopharmaceutical therapy – Daniel Badger, SA Health
Olivia Newton-John Cancer Research Institute
Preclinical evaluation of DNA damage response inhibitors and 225Ac-DOTA-girentuximab combination therapy
Saturday, 24 May 2025 | 11:00 AM – 12:30 PM
Meeting Room 204
The University of Queensland
D2 – Enabling a theranostic approach with 89Zr/177Lu in a single trifunctional ligand scaffold
Saturday, 24 May 2025 | 11:00 AM – 12:30 PM
Meeting Room 204
Telix Pharmaceuticals
A preliminary study on nnUNet-based PSMA-PET/CT lesion segmentation models: toward clinically informed training
Sunday, 25 May 2025 | 11:00 AM – 12:30 PM
Meeting Room 204
Telix Pharmaceuticals
ZOLAR, an open-label, Phase 1 study to assess safety, tolerability, dosimetry, pharmacokinetics, and imaging properties of 89Zr-olaratumab (TLX300-CDx) in soft tissue sarcoma
Sunday, 25 May 2025 | 11:00 AM – 12:30 PM
Meeting Room 203
GenesisCare
STARSTRUCK, a Phase 1b dose escalation/expansion study of the combination of 177Lu-girentuximab (TLX250) and peposertib in patients with carbonic anhydrase IX (CAIX)-expressing solid tumors
Sunday, 25 May 2025 | 11:00 AM – 12:30 PM
Meeting Room 203
Telix Pharmaceuticals
ZIRCON-CP, a confirmatory, open-label, single-arm, multicenter study to evaluate the safety, tolerability, and diagnostic performance of 89Zr-girentuximab (TLX250-CDx) to non-invasively detect ccRCC by PET/CT imaging in Chinese patients with indeterminate renal masses
Sunday, 25 May 2025 | 2:00 PM – 3:30 PM
Meeting Room 207
Telix Pharmaceuticals
Non-invasive detection of Nectin-4 and TROP2 in bladder cancer via ImmunoPET
Jones Radiology
Initial experience with 89Zr-girentuximab (TLX250-CDx)
Università Vita-Salute San Raffaele, Milan (Italy)
The emerging role of 89Zr-girentuximab (TLX250-CDx) PET/CT in the management of ccRCC: Early experience in three patients
Presenters
[1] ClinicalTrials.gov ID: NCT06520345
[2] Prostate-specific membrane antigen.
[3] A Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate (M3814).
[4] ClinicalTrials.gov ID: NCT05868174
[5] ClinicalTrials.gov ID: NCT06537596
[6] Brand name subject to final regulatory approval.
[7] Positron emission tomography.
[8] ClinicalTrials.gov ID: NCT06750419
[9] Wood et al. Chem. Sci., 2024.
[10] Imaging of prostate-specific membrane antigen with positron emission tomography/computed tomography.